Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Joris Vandenbossche; Wolfgang Jessner; Maarten van den Boer; Jeike Biewenga; Jan Martin Berke; Willem Talloen; Loeckie De Zwart; Jan Snoeys; Koen Vandyck; John Fry; Jeysen Yogaratnam

doi:10.1007/s12325-020-01249-6

Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Adv Ther. 2020 Apr;37(4):1703. doi: 10.1007/s12325-020-01249-6.

Affiliations

¹ Janssen Pharmaceutica NV, Beerse, Belgium. jvdbossc@its.jnj.com.
² Janssen Pharmaceutica NV, Beerse, Belgium.
³ Janssen Pharmaceutica NV, Merksem, Belgium.
⁴ Janssen Biopharma, Inc., South San Francisco, CA, USA.

PMID: 32133584
DOI: 10.1007/s12325-020-01249-6

Abstract

In the original article Ninth and Tenth authors were incorrectly omitted from the author group. The correct author group is Joris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, Jeike Biewenga, Jan Martin Berke, Willem Talloen, Loeckie De Zwart, Jan Snoeys, Koen Vandyck, John Fry, Jeysen Yogaratnam.

Publication types

Published Erratum